MCID: SRT003
MIFTS: 38

Sertoli-Leydig Cell Tumor malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Sertoli-Leydig Cell Tumor

About this section

Aliases & Descriptions for Sertoli-Leydig Cell Tumor:

Name: Sertoli-Leydig Cell Tumor 10 47 12 36 65
Sertoli-Leydig Cell Tumor of Intermediate Differentiation 65
Sertoli-Leydig Cell Tumor of the Ovary 45
Sertoli-Leydig Cell Tumor of Ovary 65
 
Sertoli-Leydig Cell Tumors 45
Arrhenoblastoma of Ovary 45
Androblastoma of Ovary 45
Arrhenoblastoma 45

Classifications:



External Ids:

Disease Ontology10 DOID:2997
SNOMED-CT59 34110004
MeSH36 D018310
UMLS65 C0206723, C1318541, C0003810

Summaries for Sertoli-Leydig Cell Tumor

About this section
NIH Rare Diseases:45 Sertoli-leydig cell tumors are a cancer that starts in the female ovaries. the cancer cells produce and release a male sex hormone which may cause the development of male physical characteristics (virilization), including facial hair and a deep voice. this type of tumor is sometimes called arrhenoblastoma of the ovary or a stromal tumor. sertoli-leydig cell tumors are rare tumors which account for less than 0.5% of all ovarian tumors. while they can be found in women of all age groups, they are most common in young women. treatment involves surgery and chemotherapy or radiation if the cancer has spread. because sertoli-leydig cell tumors have a low chance of spreading, if the tumor is found early, chances for survival are good. last updated: 3/25/2010

MalaCards based summary: Sertoli-Leydig Cell Tumor, also known as sertoli-leydig cell tumor of intermediate differentiation, is related to malignant sertoli-leydig cell tumor and cystic teratoma, and has symptoms including hoarseness An important gene associated with Sertoli-Leydig Cell Tumor is AFP (Alpha Fetoprotein). Affiliated tissues include ovary, breast and thyroid.

Related Diseases for Sertoli-Leydig Cell Tumor

About this section

Diseases in the Sertoli-Leydig Cell Tumor family:

Malignant Sertoli-Leydig Cell Tumor

Diseases related to Sertoli-Leydig Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 129)
idRelated DiseaseScoreTop Affiliating Genes
1malignant sertoli-leydig cell tumor34.0AFP, SYP
2cystic teratoma30.6AFP, SYP
3goiter, multinodular 1, with or without sertoli-leydig cell tumors12.6
4malignant sertoli-leydig cell tumor of ovary12.5
5leydig cell tumor11.1
6seminal vesicle adenocarcinoma10.5AFP, CALB2
7diffuse pulmonary fibrosis10.5AFP, CALB2
8fibrous synovial sarcoma10.5AFP, CALB2
9paraphimosis10.4AFP, WT1
10heart fibrosarcoma10.4AFP, WT1
11androgen insensitivity10.4
12nasal cavity adenocarcinoma10.4AFP, MUC1
13congenital nonhemolytic jaundice10.4AFP, WT1
14endometriosis of intestine10.4MUC1, WT1
15pancreatic invasive mucinous cystadenocarcinoma10.4CALB2, MUC1
16complete androgen insensitivity syndrome10.4
17fallopian tube adenosarcoma10.4CALB2, WT1
18bile duct carcinoma10.4AFP, MUC1
19spindle cell variant squamous cell breast carcinoma10.3CALB2, WT1
20renal adenoma10.3AFP, INSL3
21bartholin's gland small cell carcinoma10.3AFP, SYP
22pancreatic solid pseudopapillary carcinoma10.3AFP, SYP
23developmental dysphasia familial10.3MUC1, WT1
24myoblastoma10.3AFP, SYP
25benign peritoneal mesothelioma10.3MUC1, WT1
26mediastinal mesenchymal tumor10.3AFP, SYP
27fallopian tube teratoma10.3AFP, SYP
28multinodular goiter10.3
29sarcoma10.3
30goiter10.3
31cervicitis10.3
32cystadenoma10.3
33rhabdomyosarcoma10.3
34adult malignant schwannoma10.3MUC1, SYP
35malignant ovarian brenner tumor10.3MUC1, SYP
36median neuropathy10.3CALB2, WT1
37anovulation10.3MUC1, SYP
38male reproductive organ cancer10.3AFP, SYP
39bronchus cancer10.3CALB2, WT1
40mixed glioma10.3MUC1, SYP
41bile duct cystadenocarcinoma10.3AFP, SYP
42acantholytic squamous cell skin carcinoma10.3AFP, MUC1
43staphyloenterotoxemia10.3CALB2, WT1
44caroli disease10.3MUC1, SYP
45epidermal appendage tumor10.3MUC1, SYP
46arteriosclerosis obliterans10.3CALB2, WT1
47head and neck carcinoma10.2AFP, SYP
48colon mucinous adenocarcinoma10.2AFP, SYP
49nasopharyngeal carcinoma10.2MUC1, SYP
50hyperandrogenism10.2

Graphical network of the top 20 diseases related to Sertoli-Leydig Cell Tumor:



Diseases related to sertoli-leydig cell tumor

Symptoms for Sertoli-Leydig Cell Tumor

About this section

UMLS symptoms related to Sertoli-Leydig Cell Tumor:


hoarseness

Drugs & Therapeutics for Sertoli-Leydig Cell Tumor

About this section

Drugs for Sertoli-Leydig Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CarboplatinapprovedPhase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
2
CisplatinapprovedPhase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
3
PaclitaxelapprovedPhase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
4
EtoposideapprovedPhase 2116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
5
BleomycinapprovedPhase 214411056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
6
SuccinylcholineapprovedPhase 2141306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
7Albumin-Bound PaclitaxelPhase 22621
8Tubulin ModulatorsPhase 24279
9Topoisomerase InhibitorsPhase 24081
10Neuromuscular Blocking AgentsPhase 2327
11Peripheral Nervous System AgentsPhase 218510
12Neuromuscular Depolarizing AgentsPhase 2116
13Anti-Bacterial AgentsPhase 29140
14Neuromuscular AgentsPhase 2922
15Antimitotic AgentsPhase 24296
16Antibiotics, AntitubercularPhase 25971
17Antineoplastic Agents, PhytogenicPhase 24294
18Etoposide phosphatePhase 21169
19
GemcitabineapprovedPhase 1188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
20Immunologic FactorsPhase 118483
21Immunosuppressive AgentsPhase 110422
22Anti-Infective AgentsPhase 117220
23AntimetabolitesPhase 19454
24Antimetabolites, AntineoplasticPhase 15770
25Antiviral AgentsPhase 18071

Interventional clinical trials:

idNameStatusNCT IDPhase
1Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal TumorsRecruitingNCT01042522Phase 2
2Paclitaxel in Treating Patients With Ovarian Stromal CancerActive, not recruitingNCT00006227Phase 2
3Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological CancerCompletedNCT01652794Phase 1
4Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast CancerCompletedNCT01764789
5DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyRecruitingNCT01247597
6Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer SyndromeRecruitingNCT00565903
7Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal TumorsActive, not recruitingNCT01572467

Search NIH Clinical Center for Sertoli-Leydig Cell Tumor


Cochrane evidence based reviews: sertoli-leydig cell tumor

Genetic Tests for Sertoli-Leydig Cell Tumor

About this section

Anatomical Context for Sertoli-Leydig Cell Tumor

About this section

MalaCards organs/tissues related to Sertoli-Leydig Cell Tumor:

33
Ovary, Breast, Thyroid, Brain, Lung, Heart, Colon

Animal Models for Sertoli-Leydig Cell Tumor or affiliated genes

About this section

Publications for Sertoli-Leydig Cell Tumor

About this section

Articles related to Sertoli-Leydig Cell Tumor:

(show top 50)    (show all 128)
idTitleAuthorsYear
1
Sertoli-Leydig cell tumor of the ovary: A diagnostic dilemma. (26937481)
2016
2
Bilateral sertoli-leydig cell tumor in a primigravida: a rare case. (25002956)
2014
3
Bilateral laparoscopic gonadectomy in a patient with complete androgen insensitivity syndrome and bilateral sertoli-leydig cell tumor: a case report and brief review of the literature. (25032133)
2014
4
Ovarian Sertoli-Leydig cell tumor with heterologous elements of gastrointestinal type associated with elevated serum alpha-fetoprotein level: an unusual case and literature review. (25926909)
2014
5
Sertoli-Leydig cell tumors: hormonal profile after dynamic test with GnRH analogue: triptorelin represents a useful tool to evaluate tumoral hyperandrogenism. (25299229)
2014
6
Sertoli-leydig cell tumor of ovary- a diagnostic dilemma. (24783104)
2014
7
A case of successful salvage chemotherapy of recurrent ovarian sertoli-leydig cell tumor. (24328002)
2013
8
Cervical sarcoma botryoides and ovarian Sertoli-Leydig cell tumor: a case report and review of literature. (21847587)
2012
9
Malignant ovarian Sertoli-Leydig cell tumor localized with selective ovarian vein sampling. (23084689)
2012
10
Sertoli-Leydig cell tumor of the ovary--morphological and immunohistochemical analysis. (22635079)
2012
11
Bilateral ovarian well-differentiated Sertoli-Leydig cell tumors with heterologous elements associated with unilateral serous cystadenoma--a case report. (20736765)
2010
12
Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements. (20407320)
2010
13
Incidental detection of Sertoli-Leydig cell tumor by FDG PET/CT imaging in a patient with androgen insensitivity syndrome. (19957213)
2010
14
Hyperandrogenism due to a testosterone-secreting Sertoli-Leydig cell tumor associated with a dehydroepiandrosterone sulfate-secreting adrenal adenoma in a postmenopausal woman: case presentation and review of literature. (19289327)
2009
15
Recurrent alpha-fetoprotein secreting Sertoli-Leydig cell tumor of ovary with an unusual presentation. (19282570)
2009
16
Bilateral Sertoli-Leydig cell tumor of the ovary: a rare case report. (19136796)
2009
17
Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. (17885486)
2007
18
A rare ovarian tumor - Sertoli-Leydig cell tumor with heterologous element. (18311394)
2007
19
Immunohistochemical and ultrastructural analysis of a poorly differentiated pediatric age Sertoli-Leydig cell tumor. (17022971)
2007
20
Expression profile of ovarian tumors: distinct signature of Sertoli-Leydig cell tumor. (17177833)
2006
21
Sertoli-Leydig cell tumor of ovary with heterologous element: a case report. (16366107)
2005
22
Uterine retiform sertoli-leydig cell tumor: report of a case providing additional evidence that uterine tumors resembling ovarian sex cord tumors have a histologic and immunohistochemical phenotype of genuine sex cord tumors. (16175078)
2005
23
Sertoli-Leydig cell tumor of the ovary. (15216408)
2004
24
Overexpression of the BCL2 gene in a Sertoli-Leydig cell tumor of the ovary: a pathologic and cytogenetic study. (14734221)
2004
25
Ovarian Sertoli-Leydig cell tumor, endometrioid-like yolk sac tumor, and Y-chromosomal material. (12759534)
2003
26
Sertoli-Leydig cell tumor of the ovary, a rare cause of precocious puberty in a 12-month-old infant. (11788622)
2002
27
Ossifying well-differentiated Sertoli-Leydig cell tumor of the ovary. (10684379)
2000
28
Presence of 17 beta-hydroxysteroid dehydrogenase type 3 messenger ribonucleic acid transcript in an ovarian Sertoli-Leydig cell tumor. (9314929)
1997
29
Sertoli-Leydig cell tumor of the ovary: a case report with endocrinologic observations. (15251509)
1996
30
Ovarian serous cystadenoma associated with Sertoli-Leydig cell tumor--a case report. (8703377)
1996
31
Immunohistochemical and biochemical analysis of a human Sertoli-Leydig cell tumor: autonomous steroid production characteristic of ovarian theca cells. (9420846)
1995
32
Ovarian Sertoli-Leydig cell tumor with retiform pattern. (8771159)
1995
33
Diagnosis and resection of an oral contraceptive-suppressible Sertoli-Leydig cell tumor with preservation of fertility and a 7-year follow-up. (2523030)
1989
34
Sertoli-Leydig cell tumor associated with a mature cystic teratoma in a single ovary. (2587573)
1989
35
Ovarian Sertoli-Leydig cell tumor with elevated serum alpha-fetoprotein. (2467733)
1989
36
An ovarian Sertoli-Leydig cell tumor with heterologous mucinous gland and NSE-immunoreactive-cell. (2457358)
1988
37
Ovarian and peripheral steroid hormones in a case of Sertoli-Leydig cell tumor. (2844882)
1988
38
Raised serum alpha-fetoprotein in Sertoli-Leydig cell tumor (androblastoma) of ovary: report of two cases. (2437064)
1987
39
Ovarian Sertoli-Leydig cell tumor (androblastoma) with retiform pattern. A clinicopathologic study. (3677027)
1987
40
Bilateral Sertoli-Leydig cell tumor with heterologous elements: report of an unusual case and review of the literature. (3732587)
1986
41
Demonstration of hydroxysteroid dehydrogenases and testosterone in the Sertoli-Leydig cell tumor (androblastoma) tissue of the human ovary: an enzyme histochemical and immunohistochemical study. (2984872)
1985
42
Steroid biosynthesis in the Sertoli-Leydig cell tumor tissue of the human ovary; enzymhistochemical and immunohistochemical studies. (6425925)
1984
43
Steroid metabolism in an androblastoma (Sertoli-Leydig cell tumor): a histopathological and biochemical study. (6327547)
1984
44
A Sertoli-Leydig cell tumor and pregnancy. Clinical, endocrine, radiologic, and electron microscopic findings. (6660923)
1983
45
Metastatic Sertoli-Leydig cell tumor of the ovary during pregnancy treated by BV-CAP chemotherapy. (6177244)
1982
46
Sertoli-Leydig cell tumor of the ovary with teratomatous differentiation: clinicopathologic considerations. (7104958)
1982
47
Sertoli-Leydig cell tumor of the ovary, with an associated mucinous cystadenoma. An ultrastructural and endocrine study. (4280005)
1974
48
Ultrastructure of a human chorionic gonadotropin-and adrenocorticotropin-responsive functioning Sertoli-Leydig cell tumor (type I). (4353887)
1973
49
Ultrastructure of an intermediate Sertoli-Leydig cell tumor. A histogenetic misnomer. (4311418)
1969
50
Ultrastructure of ovarian stromal cell tumors. Sertoli-Leydig cell tumor and lipid cell tumor. (5681434)
1968

Variations for Sertoli-Leydig Cell Tumor

About this section

Expression for genes affiliated with Sertoli-Leydig Cell Tumor

About this section
Search GEO for disease gene expression data for Sertoli-Leydig Cell Tumor.

Pathways for genes affiliated with Sertoli-Leydig Cell Tumor

About this section

GO Terms for genes affiliated with Sertoli-Leydig Cell Tumor

About this section

Biological processes related to Sertoli-Leydig Cell Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1SMAD protein signal transductionGO:00603959.6AFP, INHA

Sources for Sertoli-Leydig Cell Tumor

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet